Anemia, hematinic deficiencies, and gastric parietal cell antibody positivity in burning mouth syndrome patients with or without hyperhomocysteinemia

Meng-Ling Chianga,b,c, Chun-Pin Chiangd,e,f,g, Andy Sun e,f*

a Department of Pediatric Dentistry, Chang Gung Memorial Hospital, Taipei, Taiwan
b Department of Oral Pathology and Oral Diagnosis, Chang Gung Memorial Hospital, Taipei, Taiwan
c College of Medicine, Chang Gung University, Taoyuan, Taiwan
d Department of Dentistry, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan
e Graduate Institute of Clinical Dentistry, School of Dentistry, National Taiwan University, Taipei, Taiwan
f Department of Dentistry, National Taiwan University Hospital, College of Medicine, National Taiwan University, Taipei, Taiwan
g Graduate Institute of Oral Biology, School of Dentistry, National Taiwan University, Taipei, Taiwan

KEYWORDS
Burning mouth syndrome; Hyperhomocysteinemia; Normocytic anemia; Pernicious anemia; Vitamin B12 deficiency

Abstract Background/purpose: Our previous study found that 170 of 884 burning mouth syndrome (BMS) patients have hyperhomocysteinemia. This study assessed whether these 170 BMS patients with hyperhomocysteinemia had significantly higher frequencies of anemia, hematinic deficiencies, and serum gastric parietal cell antibody (GPCA) positivity than 714 BMS patients without hyperhomocysteinemia or 442 healthy control subjects.

Materials and methods: The blood hemoglobin (Hb) and serum iron, vitamin B12, folic acid, homocysteine, and GPCA levels in 170 BMS patients with hyperhomocysteinemia, 714 BMS patients without hyperhomocysteinemia, and 442 healthy control subjects were measured and compared.

Results: We found that 170 BMS patients with hyperhomocysteinemia had significantly higher frequencies of macrocytosis, blood Hb and serum iron, vitamin B12, and folic acid deficiencies, and serum GPCA positivity than 442 healthy control subjects (all P-values < 0.001) or 714 BMS patients without hyperhomocysteinemia (all P-values < 0.05). Anemia was found in 77 of 170
Burning mouth syndrome patients with hyperhomocysteinemia and in 98 of 714 BMS patients without hyperhomocysteinemia. Normocytic anemia (47 cases) and pernicious anemia (15 cases) were the two most common types of anemia in 170 BMS patients with hyperhomocysteinemia. Moreover, normocytic anemia (48 cases), iron deficiency anemia (21 cases), and thalassemia trait-induced anemia (21 cases) were the three most common types of anemia in 714 BMS patients without hyperhomocysteinemia.

**Conclusion:** BMS patients with hyperhomocysteinemia had significantly higher frequencies of macrocytosis, anemia, serum iron, vitamin B12, and folic acid deficiencies, and serum GPCA positivity than healthy control subjects or BMS patients without hyperhomocysteinemia. © 2020 Association for Dental Sciences of the Republic of China. Publishing services by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

**Introduction**

Burning mouth syndrome (BMS) is characterized by the presence of burning sensation of the oral mucosa, but oral examination reveals none of clinically apparent oral mucosal alterations. BMS occurs more frequently in middle-aged and elderly women. Our previous study found that 170 (19.2%) of 884 BMS patients have hyperhomocysteinemia. Serum homocysteine level is a biomarker of cardiovascular diseases. Higher serum homocysteine levels are associated with increased rates of coronary heart disease and stroke, because previous studies have demonstrated that high serum homocysteine level can cause oxidative stress, damage endothelium, and enhance thrombogenicity. Homocysteine is formed during methionine metabolism. Both vitamin B12 and folic acid act as coenzymes for the conversion of homocysteine to methionine. Moreover, vitamin B6 is a coenzyme for the conversion of homocysteine to cysteine. Therefore, patients with vitamin B12, folic acid, and/or vitamin B6 deficiencies may have hyperhomocysteinemia. Furthermore, the gastric parietal cell antibody (GPCA) can destroy gastric parietal cells, resulting in lack of intrinsic factors and hypochlorhydria. Intrinsic factor deficiency may lead to malabsorption of vitamin B12 from terminal ileum and finally the vitamin B12 deficiency. In addition, decreased gastric secretion of hydrochloric acid may cause iron malabsorption and subsequent iron deficiency. Thus, it is interesting to know whether BMS patients with hyperhomocysteinemia are prone to have significantly higher frequencies of anemia, serum iron, vitamin B12, and folic acid deficiencies, and serum GPCA positivity than BMS patients without hyperhomocysteinemia or healthy control subjects.

In this study, we divided the 884 BMS patients into two groups: one group containing 170 BMS patients with hyperhomocysteinemia and the other group consisting of 714 BMS patients without hyperhomocysteinemia. We tried to find out whether the 170 BMS patients with hyperhomocysteinemia had significantly higher frequencies of macrocytosis, anemia, serum iron, vitamin B12, and folic acid deficiencies, and serum GPCA positivity than 714 BMS patients without hyperhomocysteinemia or 442 healthy control subjects.

**Materials and methods**

**Subjects**

This study consisted of 170 (69 men and 101 women, age range 18–90 years, mean age 56.2 ± 17.6 years) BMS patients with hyperhomocysteinemia and 714 (143 men and 571 women, age range 18–87 years, mean age 56.1 ± 13.7 years) BMS patients without hyperhomocysteinemia. For two BMS patients, one age (±2 years of each patient’s age) and sex-matched healthy control subject was selected. Thus, 442 age- and sex-matched healthy control subjects (106 men and 336 women, age range 18–90 years, mean 57.5 ± 13.5 years) were selected and included in this study. These 170 BMS patients with hyperhomocysteinemia, 714 BMS patients without hyperhomocysteinemia, and 442 healthy control subjects were retrieved from our previous study. All the BMS patients and healthy control subjects were seen consecutively, diagnosed, and treated in the Department of Dentistry, National Taiwan University Hospital (NTUH) from July 2007 to July 2017. Patients were diagnosed as having BMS when they complained of burning sensation and other symptoms of the oral mucosa but no apparent clinical oral mucosal abnormality was found. The detailed inclusion and exclusion criteria for our BMS patients and healthy control subjects have been described previously. In addition, none of the BMS patients had taken any prescription medication for BMS at least 3 months before entering the study.

The blood samples were drawn from 170 BMS patients with hyperhomocysteinemia, 714 BMS patients without hyperhomocysteinemia, and 442 healthy control subjects for the measurement of complete blood count, serum iron, vitamin B12, folic acid, and homocysteine levels, and the serum GPCA positivity. All BMS patients and healthy control subjects signed the informed consents before entering the study. This study was reviewed and approved by the Institutional Review Board at the NTUH (201212066RIND).
Determinations of complete blood counts and serum iron, vitamin B12, folic acid, and homocysteine levels

The complete blood count and serum iron, vitamin B12, folic acid, and homocysteine levels were determined by the routine tests performed in the Department of Laboratory Medicine, NTUH.1,14,15

Determination of serum gastric parietal cell antibody level

The serum GPCA level was detected by the indirect immunofluorescence assay with rat stomach as a substrate as described previously.1 Sera were scored as positive when they produced fluorescence at a dilution of 10-fold or more.

Statistical analysis

Comparisons of the mean corpuscular volume (MCV) and mean blood hemoglobin (Hb) and serum iron, vitamin B12, folic acid, and homocysteine levels between 170 BMS patients with hyperhomocysteinemia or 714 BMS patients without hyperhomocysteinemia were performed by Student’s t-test. The result was considered to be significant if the P-value was less than 0.05.

Results

Comparisons of MCV and mean blood Hb and serum iron, vitamin B12, folic acid, and homocysteine levels between any two of three groups of 170 BMS patients with hyperhomocysteinemia, 714 BMS patients without hyperhomocysteinemia, and 442 healthy control subjects are shown in Table 1. Because men usually had higher blood levels of Hb and iron than women, these two mean levels were calculated separately for men and women. We found significantly lower mean blood Hb (for men and women) and serum iron (for men and women), vitamin B12, and folic acid levels as well as significantly higher MCV and mean serum homocysteine level in 170 BMS patients with hyperhomocysteinemia than in 442 healthy control subjects (all P-values < 0.01, Table 1). Moreover, we also found significantly lower mean blood Hb (for men and women) and serum iron (for men only), vitamin B12, and folic acid levels as well as significantly higher MCV and mean serum homocysteine level in 714 BMS patients with hyperhomocysteinemia than in 714 BMS patients without hyperhomocysteinemia (all P-values < 0.001, Table 1). Furthermore, 714 BMS patients without hyperhomocysteinemia also had significantly lower MCV, mean

| Group                        | MCV (fL) | Hb (g/dL) | Iron (µg/dL) | Vitamin B12 (pg/mL) | Folic acid (ng/mL) | Homocysteine (µM) |
|------------------------------|----------|-----------|--------------|---------------------|--------------------|-------------------|
| BMS patients with hyperhomocysteinemia |          |           |              |                     |                    |                   |
| (n = 170)                    | 91.7 ± 8.5 | 13.9 ± 1.7 | 12.5 ± 1.3   | 81.2 ± 23.4         | 84.6 ± 30.0        | 382.0 ± 233.2     |
| P-value                      |          | <0.001   | <0.001       | <0.001              | <0.001             | <0.001            |
| BMS patients without hyperhomocysteinemia |          |           |              |                     |                    |                   |
| (n = 714)                    | 89.1 ± 6.9 | 14.9 ± 1.2 | 13.2 ± 1.1   | 97.8 ± 26.7         | 90.1 ± 32.0        | 700.9 ± 237.7     |
| P-value                      |          | <0.001   | <0.001       | <0.001              | 0.109              | <0.001            |
| Healthy control subjects     | 90.4 ± 3.6 | 15.1 ± 0.8 | 13.5 ± 0.7   | 105.2 ± 28.0        | 97.8 ± 27.2        | 694.2 ± 220.2     |
| (n = 442)                    |           |          |              |                     |                    |                   |

* Comparisons of means of parameters between 170 BMS patients with hyperhomocysteinemia or 714 BMS patients without hyperhomocysteinemia and 442 healthy control subjects by Student’s t-test.

** Comparisons of means of parameters between 170 BMS patients with hyperhomocysteinemia and 714 BMS patients without hyperhomocysteinemia by Student’s t-test.
blood Hb (for women only) and serum iron (for men and women) and homocysteine levels than healthy control subjects (all P-values < 0.05, Table 1).

According to the World Health Organization (WHO) criteria, microcytosis of erythrocyte was defined as having MCV < 80 fL, macrocytosis of erythrocyte was defined as having MCV > 100 fL, and men with Hb < 13 g/dL and women with Hb < 12 g/dL were defined as having Hb deficiency or anemia. Furthermore, patients with the serum iron level < 60 µg/dL, the serum vitamin B12 level < 200 pg/mL, or the serum folic acid level < 4 ng/mL were defined as having iron, vitamin B12 or folic acid deficiency, respectively. In addition, patients with the blood homocysteine level > 12.3 µM (which was the mean serum homocysteine level of healthy control subjects plus two standard deviations) were defined as having hyperhomocysteinemia. By the above-mentioned definitions, 5.3%, 16.5%, 45.3%, 22.9%, 20.6%, 8.2%, and 18.8% of 170 BMS patients with hyperhomocysteinemia and 8.3%, 2.5%, 13.7%, 14.6%, 1.0%, 0.8%, and 10.8% of 714 BMS patients without hyperhomocysteinemia were diagnosed as having microcytosis, macrocytosis, blood Hb and serum iron, vitamin B12, and folic acid deficiencies, and serum GPCA positivity, respectively. We found that 170 BMS patients with hyperhomocysteinemia had significantly higher frequencies of microcytosis, macrocytosis, blood Hb and serum iron deficiencies, and serum GPCA positivity than healthy control subjects (all P-values < 0.005, Table 1).

We also found that 77 (45.3%) of 170 BMS patients with hyperhomocysteinemia and 98 (13.7%) of 714 BMS patients without hyperhomocysteinemia had anemia (defined as having an Hb concentration < 13 g/dL for men and <12 g/dL for women). Of the 77 anemic BMS patients with hyperhomocysteinemia, 15 had pernicious anemia (PA, defined as having anemia, an MCV > 100 fL, a serum vitamin B12 level < 200 pg/mL, and the presence of serum GPCA positivity), 17–19 9 had macrocytic anemia (defined as having anemia and an MCV > 100 fL) other than PA, 17–19 47 had normocytic anemia (defined as having anemia and an MCV between 80.0 fL and 99.9 fL), 24–27 6 had thalassemia trait-induced anemia (defined as having anemia, a RBC count > 5.0 M/µL, an MCV < 74 fL, and a Mentzer index (MCV/RBC) < 13) (Table 3). Of the 98 anemic BMS patients without hyperhomocysteinemia, 6 had macrocytic anemia other than PA, 48 had normocytic anemia, 21 had iron deficiency anemia (IDA), 21 had thalassemia trait-induced anemia, and two had microcytic anemia other than IDA and thalassemia trait-induced anemia (Table 3).

Comparisons of frequencies of macrocytic, normocytic or microcytic anemia between 170 BMS patients with hyperhomocysteinemia and 714 BMS patients without hyperhomocysteinemia are shown in Table 4. We found that 170 BMS patients with hyperhomocysteinemia had significantly higher frequencies of macrocytic anemia and normocytic anemia than 714 BMS patients without hyperhomocysteinemia (both P-values < 0.001, Table 4). Distribution of patients with low, moderate, or high serum levels of iron, vitamin B12, and folic acid in 170 BMS patients with hyperhomocysteinemia and in 714 BMS patients without hyperhomocysteinemia is shown in Table 5. We found that 170 BMS patients with

| Group | Microcytosis (MCV < 80 fL) | Macrocytosis (MCV > 100 fL) | Hb deficiency (Men < 13 g/dL, women < 12 g/dL) | Iron deficiency (<60 µg/dL) | Vitamin B12 deficiency (<200 pg/mL) | Folic acid deficiency (<4 ng/mL) | GPCA positivity |
|-------|--------------------------|-----------------------------|-----------------------------------------------|-----------------------------|----------------------------------|-------------------------------|----------------|
| BMS patients with hyperhomocysteinemia (n = 170) | 9 (5.3) | 28 (16.5) | 77 (45.3) | 39 (22.9) | 35 (20.6) | 14 (8.2) | 32 (18.8) |
| aP-value | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 |
| bP-value | 0.252 | 0.001 | 0.001 | 0.011 | 0.001 | 0.001 | 0.006 |
| BMS patients without hyperhomocysteinemia (n = 714) | 59 (8.3) | 18 (2.5) | 98 (13.7) | 104 (14.6) | 7 (1.0) | 6 (0.8) | 77 (10.8) |
| aP-value | <0.001 | 0.002 | <0.001 | <0.001 | 0.090 | 0.131 | <0.001 |
| Healthy control subjects (n = 442) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) | 8 (1.8) |

a Comparisons of frequencies of parameters between 170 BMS patients with hyperhomocysteinemia and 714 BMS patients without hyperhomocysteinemia and 442 healthy control subjects by chi-square test.

b Comparisons of frequencies of parameters between 170 BMS patients with hyperhomocysteinemia and 714 BMS patients without hyperhomocysteinemia by chi-square test.
hyperhomocysteinemia had significantly higher frequencies of serum iron, vitamin B12, and folic acid deficiencies as well as significantly higher frequencies of serum vitamin B12 between 200 and 800 pg/mL and folic acid between 4 and 15 ng/mL than 714 BMS patients without hyperhomocysteinemia (all \( P \)-values < 0.05, Table 5). However, 714 BMS patients without hyperhomocysteinemia had significantly higher frequencies of patients with serum iron level \( \geq 100 \) mg/dL, vitamin B12 level \( \geq 800 \) pg/mL or folic acid level \( \geq 15 \) ng/mL than 170 BMS patients with hyperhomocysteinemia (Table 5).

### Discussion

In this study, hyperhomocysteinemia was discovered in 170 (19.2%) of 884 BMS patients.1 Our previous study also found hyperhomocysteinemia in 127 (11.9%) of 1064 atrophic glossitis patients,32 in 52 (14.8%) of 352 oral lichen planus patients,30 in 21 (7.7%) of 273 recurrent aphthous stomatitis patients,31 in 9 (14.3%) of 63 Behcet’s disease patients,32 and in 29 (22.1%) of 131 oral precancer patients.33 These findings suggest that among the five oral mucosal disease patients reported, the prevalence of hyperhomocysteinemia is highest in oral precancer patients and lowest in recurrent aphthous stomatitis patients.

Our previous study found that 170 of 884 BMS patients have hyperhomocysteinemia.1 Of 170 BMS patients with hyperhomocysteinemia, 9 (5.3%) had microcytosis, 28 (16.5%) macrocytosis, 77 (45.3%) anemia, 39 (22.9%) serum iron, 35 (20.6%) vitamin B12, and 14 (8.2%) folic acid deficiencies, and 32 (18.8%) serum GPCA positivity. Of the 884 BMS patients, 68 (7.7%) had microcytosis, 46 (5.2%) macrocytosis, 175 (19.8%) anemia, 143 (16.2%) serum iron, 85 (9.6%) vitamin B12, and 36 (4.1%) folic acid deficiencies.

### Table 3

Anemia types and hematinic deficiencies in 77 anemic burning mouth syndrome (BMS) patients with hyperhomocysteinemia and in 98 anemic BMS patients without hyperhomocysteinemia.

| Anemia type                      | Patient number (%) | Mean corpuscular volume (fL) | Iron deficiency (<60 µg/dL) | Vitamin B12 deficiency (<200 pg/mL) | Folic acid deficiency (<4 ng/mL) |
|----------------------------------|--------------------|-----------------------------|-----------------------------|-----------------------------------|---------------------------------|
| BMS patients with hyperhomocysteinemia (\( n = 170 \)) |                    |                             |                             |                                   |                                 |
| Pernicious anemia               | 15 (19.5)          | \( \geq 100 \)             | 5 (33.3)                    | 15 (100.0)                        | 0 (0.0)                         |
| Other macrocytic anemia         | 9 (11.7)           | \( \geq 100 \)             | 2 (22.2)                    | 5 (55.6)                          | 0 (0.0)                         |
| Normocytic anemia               | 47 (61.0)          | 80–99.9                     | 24 (51.1)                   | 4 (8.5)                           | 7 (14.9)                        |
| Thalassemia trait-induced anemia| 6 (7.8)            | <74                         | 2 (33.3)                    | 2 (33.3)                          | 1 (16.7)                        |
| Total                            | 77 (100.0)         |                             | 33 (42.9)                   | 26 (33.8)                         | 8 (10.4)                        |
| BMS patients without hyperhomocysteinemia (\( n = 714 \)) |                    |                             |                             |                                   |                                 |
| Other macrocytic anemia         | 6 (6.1)            | \( \geq 100 \)             | 3 (50.0)                    | 0 (0.0)                           | 0 (0.0)                         |
| Normocytic anemia               | 48 (49.0)          | 80–99.9                     | 18 (37.5)                   | 0 (0.0)                           | 0 (0.0)                         |
| Iron deficiency anemia          | 21 (21.4)          | <80                         | 21 (100.0)                  | 0 (0.0)                           | 0 (0.0)                         |
| Thalassemia trait-induced anemia| 21 (21.4)          | <74                         | 5 (23.8)                    | 0 (0.0)                           | 1 (4.8)                         |
| Other microcytic anemia         | 2 (2.1)            | <80                         | 0 (0.0)                     | 0 (0.0)                           | 0 (0.0)                         |
| Total                            | 98 (100.0)         |                             | 47 (48.0)                   | 0 (0.0)                           | 1 (1.0)                         |

\( ^{a} \) Comparison of frequencies of macrocytic, normocytic or microcytic anemia between 170 BMS patients with hyperhomocysteinemia and 714 BMS patients without hyperhomocysteinemia by chi-square test.

### Table 4

Comparisons of frequencies of macrocytic, normocytic or microcytic anemia between 170 burning mouth syndrome (BMS) patients with hyperhomocysteinemia and 714 BMS patients without hyperhomocysteinemia.

| Anemia type                      | Patient number (%) | \( ^{a} \) P-value |
|----------------------------------|--------------------|--------------------|
| BMS patients with hyperhomocysteinemia (\( n = 170 \)) |                    |                    |
| Macrocytic anemia               | 24 (14.1)          | \(<0.001>          |
| Normocytic anemia               | 47 (27.7)          | \(<0.001>          |
| Microcytic anemia               | 6 (3.5)            | 0.250              |
| Total                            | 77 (45.3)          | \(<0.001>          |
| BMS patients without hyperhomocysteinemia (\( n = 714 \)) |                    |                    |
| Macrocytic anemia               | 6 (0.8)            |                    |
| Normocytic anemia               | 48 (6.7)           |                    |
| Microcytic anemia               | 44 (6.2)           |                    |
| Total                            | 98 (13.7)          |                    |

\( ^{a} \) Comparison of frequencies of macrocytic, normocytic or microcytic anemia between 170 BMS patients with hyperhomocysteinemia and 714 BMS patients without hyperhomocysteinemia by chi-square test.
42 (4.8%) vitamin B12, and 20 (2.3%) folic acid deficiencies, and 109 (12.3%) serum GPCA positivity. Thus, when hyperhomocysteinemia is used as a biomarker, it can detect 13.2%, 60.9%, 44.0%, 27.3%, 83.3%, 70.0%, and 29.4% of BMS patients with microcytosis, macrocytosis, anemia, and serum iron, vitamin B12, and folic acid deficiencies, and serum GPCA positivity, respectively, indicating that hyperhomocysteinemia is a pretty good biomarker for screening the BMS patients with macrocytosis, anemia, serum vitamin B12 deficiency, or serum folic acid deficiency. Moreover, when a physician wants to check the serum vitamin B12 and folic acid levels for a patient who is suspected to have serum vitamin B12 and/or folic acid deficiencies, concomitant examination of the serum homocysteine level is necessary. Furthermore, when the patients are discovered to have hyperhomocysteinemia, they are suggested to give vitamin B12 and/or folic acid supplement treatments even if they have a moderate serum vitamin B12 level (up to 600 pg/mL) or folic acid level (up to 14 ng/mL). Compared to WHO definitions for vitamin B12, folic acid and iron deficiencies, our previous study used slightly higher cutoff points for serum vitamin B12 (≤450 pg/mL), folic acid (≤6 ng/mL) or iron (≤70 μg/dL for men and ≤65 μg/dL for women) level to start the relatively high doses of hematocin supplementation treatments for 399 BMS patients regardless of having hyperhomocysteinemia or not. We found that supplementations with vitamin BC capsules plus corresponding deficient hematocins (iron, vitamin B12, and folic acid) for those BMS patients with specific hematocic deficiencies or with vitamin BC capsules only for those BMS patients without hematocic deficiencies can reduce the abnormally high serum homocysteine levels to normal levels in BMS patients. In addition, complete regression of oral symptoms (such as burning sensation of oral mucosa, dry mouth, numbness of the oral mucosa, and loss or dysfunction of taste) is found in 177 (44.4%) of 399 BMS patients treated with the above-mentioned regimens.

The GPCA is a gastric autoantibody that can cause destruction of gastric parietal cells, resulting in lack of intrinsic factor production and ileal malabsorption of vitamin B12 that finally leads to significantly higher frequencies of macrocytosis, anemia (including macrocytic, normocytic, and microcytic anemias), and vitamin B12 deficiency in our 170 BMS patients with hyperhomocysteinemia than in our 714 BMS patients without hyperhomocysteinemia. However, the serum GPCA positivity was found in only 32 (18.8%) of our 170 BMS patients with hyperhomocysteinemia. Vitamin B12 and/or folic acid deficiencies also play important roles in causing hyperhomocysteinemia in patients. By WHO definitions, vitamin B12/folic acid deficiency was noted in 49 (28.8%) of our 170 BMS patients with hyperhomocysteinemia. Moreover, serum GPCA positivity and/or vitamin B12/folic acid deficiency were found in 63 (37.1%) of our 170 BMS patients with hyperhomocysteinemia. These findings suggest that there may be other factors causing hyperhomocysteinemia in our 107 hyperhomocysteinemic BMS patients without serum GPCA positivity and/or vitamin B12/folic acid deficiency. Chronic consumption of alcohol or tobacco has been shown as the possible causes resulting in increased serum levels of homocysteine in patients. In addition, other causes of hyperhomocysteinemia include a dysfunction of enzymes and cofactors associated with the process of homocysteine biosynthesis (main cause), excessive methionine intake, certain diseases (chronic renal failure, hypothyroidism, anemia, and malignant tumors), and side effects of some drugs (cholestyramine, metformin, methotrexate, nicotinic acid, and fibric acid derivatives).

In this study, we showed serum iron deficiency in 39 (22.9%); 10 patients also had serum GPCA positivity) of 170 BMS patients with hyperhomocysteinemia and in 104 (14.6%); 8 patients also had serum GPCA positivity) of 714 BMS patients without hyperhomocysteinemia. These findings indicate that the serum GPCA-induced reduction of

| Table 5 Distribution of patients with low, moderate, or high serum levels of iron, vitamin B12, and folic acid in 170 burning mouth syndrome (BMS) patients with hyperhomocysteinemia and in 714 BMS patients without hyperhomocysteinemia. |
|---|---|---|
| Group | Patient number (%) | aP-value |
| **Serum iron level (μg/dL)** | | |
| < 60 | 39 (22.9) | 104 (14.6) | 0.011 |
| Between 60 and 100 | 89 (52.4) | 316 (44.2) | 0.069 |
| ≥ 100 | 42 (24.7) | 294 (41.2) | <0.001 |
| **Serum vitamin B12 level (pg/mL)** | | |
| < 200 | 35 (20.6) | 7 (1.0) | <0.001 |
| Between 200 and 800 | 118 (69.4) | 421 (59.0) | 0.015 |
| ≥ 800 | 17 (10.0) | 286 (40.0) | <0.001 |
| **Serum folic acid level (ng/mL)** | | |
| < 4 | 14 (8.3) | 6 (0.8) | <0.001 |
| Between 4 and 15 | 108 (63.5) | 384 (53.8) | 0.027 |
| ≥ 15 | 48 (28.2) | 324 (45.4) | <0.001 |

* Comparisons of frequencies of patients with low, moderate, or high serum levels of iron, vitamin B12, and folic acid between 170 BMS patients with hyperhomocysteinemia and 714 BMS patients without hyperhomocysteinemia by chi-square test.
gastric hydrochloric acid secretion only play a minor role in causing serum iron deficiency in our 170 BMS patients with hyperhomocysteinemia and 714 BMS patients without hyperhomocysteinemia. Thus, there may be other factors (such as chronic blood loss related to excessive menstrual flow or gastrointestinal diseases, a reduced intake of iron during old-age stage, a decreased absorption of iron in patients who take antacids, H2-receptor antagonists, or proton pump inhibitors, and others) that result in serum iron deficiency in our BMS patients.13

This study also found folic acid deficiency in 14 (8.2%) of 170 BMS patients with hyperhomocysteinemia and in only 6 (0.8%) of 714 BMS patients without hyperhomocysteinemia. Folic acid deficiency can be due to several factors such as poor nutritional intake, malabsorption, hepatobiliary dysfunction, increased folate catabolism, and medication (e.g., methotrexate, 5-fluoro-uracil, phenytoin, etc.).37 However, the exact etiologies resulting in folic acid deficiency in our 170 BMS patients with hyperhomocysteinemia and in our 714 BMS patients without hyperhomocysteinemia may need further studies.

This study also demonstrated a significantly higher frequency of anemia in 170 BMS patients with hyperhomocysteinemia (45.3%) than in 714 BMS patients without hyperhomocysteinemia (13.7%). The normocytic anemia (61.0%), PA (19.5%), and macrocytic anemia other than PA (11.7%) were the three most common types of anemia in our 710 BMS patients with hyperhomocysteinemia. Moreover, the normocytic anemia (49.0%), IDA (21.4%), and thalassemia trait-induced anemia (21.4%) were the three most common types of anemia in our 714 BMS patients without hyperhomocysteinemia. Further analyses demonstrated that macrocytic anemia and normocytic anemia occurred more commonly in 170 BMS patients with hyperhomocysteinemia than in 714 BMS patients without hyperhomocysteinemia. This result could be partially due to significantly higher frequencies of serum vitamin B12 and folic acid deficiencies and serum GPCA positivity in our 170 BMS patients with hyperhomocysteinemia than in our 714 BMS patients without hyperhomocysteinemia. The normocytic anemia in BMS patients could also be attributed to a mixture of conditions producing microcytic and macrocytic anemias, chronic diseases, inflammatory diseases, infections, bone marrow hypoplasia, decreased production of erythropoietin or a poor response to erythropoietin, hemolytic disorders, mild but persistent blood loss from gastrointestinal tract, and cytokine-induced suppression of erythropoiesis.24–27 However, further studies are needed to explore whether our BMS patients have the above-mentioned conditions associated with normocytic anemia.

In conclusion, BMS patients with hyperhomocysteinemia had significantly higher frequencies of macrocytosis, anemia, serum iron, vitamin B12, and folic acid deficiencies, and serum GPCA positivity than healthy control subjects or BMS patients without hyperhomocysteinemia.

Declaration of Competing Interest

The authors have no conflicts of interest relevant to this article.

Acknowledgements

This study was supported by the grants (No. 102-2314-B-002-125-MY3 and No. 105-2314-B-002-075-MY2) of Ministry of Science and Technology, Taiwan.

References

1. Chiang CP, Wu YH, Wu YC, Chang JYF, Wang YP, Sun A. Anemia, hematocrit deficiencies, hyperhomocysteinemia, and serum gastric parietal cell antibody positivity in 884 patients with burning mouth syndrome. J Formos Med Assoc 2020;119:544–52.
2. Spence JD. Homocysteine-lowering therapy: a role in stroke prevention? Lancet Neurol 2007;6:830–8.
3. Chanarin I, Deacon R, Lumb M, Perry J. Cobalamin-folate interaction. Blood Rev 1989;3:211–5.
4. Lonn E, Yusuf S, Arnold MJ, et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med 2006;354:1567–77.
5. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998;338:1042–50.
6. Harker LA, Harlan JM, Ross R. Effect of sulfinpyrazone on homocysteine induced endothelial injury and arteriosclerosis in baboons. Circ Res 1983;53:731–9.
7. Harker LA, Slichter SJ, Scott CR, Ross R. Homocysteinaemia: vascular injury and arterial thrombosis. N Engl J Med 1974;291:537–43.
8. Taylor KB, Rott IM, Doniach D, Coshman KG, Shapland C. Autoimmune phenomena in pernicious anemia: gastric antibodies. BMJ 1962;2:1347–52.
9. Snow CF. Laboratory diagnosis of vitamin B12 and folate deficiency. A guide for the primary care physician. Arch Intern Med 1999;159:1289–98.
10. Lahner E, Annibale B. Pernicious anemia: new insights from a gastroenterological point of view. World J Gastroenterol 2009;15:5121–8.
11. Oh RC, Brown DL. Vitamin B12 deficiency. Am Fam Physician 2003;67:979–86.
12. Aslinia F, Mazza JJ, Yale SH. Megaloblastic anemia and other causes of macrocytosis. Clin Med Res 2006;4:236–41.
13. Wu YC, Wang YP, Chang JYF, Cheng SJ, Chen HM, Sun A. Oral manifestations and blood profile in patients with iron deficiency anemia. J Formos Med Assoc 2014;113:83–7.
14. Lin HP, Wang YP, Chen HM, Kuo YS, Lang MJ, Sun A. Significant association of hematocrit deficiencies and high blood homocysteine levels with burning mouth syndrome. J Formos Med Assoc 2013;112:319–25.
15. Sun A, Lin HP, Wang YP, Chen HM, Cheng SJ, Chiang CP. Significant reduction of serum homocysteine level and oral symptoms after different vitamin supplement treatments in patients with burning mouth syndrome. J Oral Pathol Med 2013;42:474–9.
16. Lin HP, Wu YH, Wang YP, Wu YC, Chang JYF, Sun A. Anemia and hematocrit deficiencies in gastric parietal cell antibody-positive and –negative oral mucosal disease patients with macrocytosis. J Formos Med Assoc 2017;116:613–9.
17. Sun A, Wang YP, Lin HP, Jia JS, Chiang CP. Do all the patients with gastric parietal cell antibodies have pernicious anemia? Oral Dis 2013;19:381–6.
18. Sun A, Chang JYF, Wang YP, Cheng SJ, Chen HM, Chiang CP. Do all the patients with vitamin B12 deficiency have pernicious anemia? J Oral Pathol Med 2016;45:23–7.
19. Chang JYF, Wang YP, Wu YC, Cheng SJ, Chen HM, Sun A. Hematocrit deficiencies and pernicious anemia in oral mucosal...
disease patients with macrocytosis. J Formos Med Assoc 2015;114:736–41.

20. WHO/UNICEF/UNU. Iron deficiency anaemia assessment, prevention, and control: a guide for programme managers. Geneva, Switzerland: World Health Organization, 2001.

21. Shine JW. Microcytic anemia. Am Fam Physician 1997;55:2455–62.

22. Morris MS, Jacques PF, Rosenberg IH, Selhub J. Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification. Am J Clin Nutr 2007;85:193–200.

23. de Benoist B. Conclusions of a WHO technical consultation on folate and vitamin B12 deficiencies. Food Nutr Bull 2008;29(suppl):S238–44.

24. Brill JR, Baumgardner DJ. Normocytic anemia. Am Fam Physician 2000;62:2255–63.

25. Koury MJ. Abnormal erythropoiesis and the pathophysiology of chronic anemia. Blood Rev 2014;28:49–66.

26. Koury MJ, Rhodes M. How to approach chronic anemia. Hematology Am Soc Hematol Educ Program 2012;2012:183–90.

27. Means Jr RT. Pathogenesis of the anemia of chronic disease: a cytokine-mediated anemia. Stem Cell 1995;13:32–7.

28. Wang YM, Chang JYF, Wu YC, Cheng SJ, Chen HM, Sun A. Oral manifestations and blood profile in patients with thalassemia trait. J Formos Med Assoc 2013;112:761–5.

29. Chiang CP, Chang JYF, Wang YM, Wu YC, Wu YH, Sun A. Significantly higher frequencies of anemia, hematocrit deficiencies, hyperhomocysteinemia, and serum gastrin parietal cell antibody positivity in atrophic glossitis patients. J Formos Med Assoc 2018;117:1065–71.

30. Chen HM, Wang YM, Chang JYF, Wu YC, Cheng SJ, Sun A. Significant association of deficiencies of hemoglobin, iron, folic acid, and vitamin B12 and high homocysteine level with oral lichen planus. J Formos Med Assoc 2015;114:124–9.

31. Sun A, Chen HM, Cheng SJ, et al. Significant association of deficiency of hemoglobin, iron, vitamin B12, and folic acid and high homocysteine level with recurrent aphthous stomatitis. J Oral Pathol Med 2015;44:300–5.

32. Kuo YS, Chang JYF, Wang YM, Wu YC, Wu YH, Sun A. Significantly higher frequencies of hemoglobin, iron, vitamin B12, and folic acid deficiencies and of hyperhomocysteinemia in patients with Behçet’s disease. J Formos Med Assoc 2018;117:932–8.

33. Wu YH, Wu YC, Chu FY, Cheng SJ, Sun A, Chen HM. Significantly higher frequencies of hematocrit deficiencies and hyperhomocysteinemia in oral precancer patients. J Formos Med Assoc 2019;118:1299–307.

34. Bleich S, Bleich K, Kropp S, et al. Moderate alcohol consumption in social drinkers raises plasma homocysteine levels: a contradiction to the ‘French Paradox’? Alcohol Alcohol 2001;36:189–92.

35. Bleich S, Carl M, Bayerlein K, et al. Evidence of increased homocysteine levels in alcoholism: the Franconian alcoholism research studies (FARS). Alcohol Clin Exp Res 2005;29:334–6.

36. Kim J, Kim H, Roh H, Kwon Y. Causes of hyperhomocysteinemia and its pathological significance. Arch Pharm Res (Seoul) 2018;41:372–83.

37. Chang JYF, Wang YM, Wu YC, Cheng SJ, Chen HM, Sun A. Hematocrit deficiencies and anemia statuses in oral mucosal disease patients with folic acid deficiency. J Formos Med Assoc 2015;114:806–12.